Technique hastens COVID-19 antibody discovery
Mar. 10, 2022—Optimization of a technique developed at Vanderbilt University Medical Center enables rapid and efficient identification of neutralizing monoclonal antibodies against the virus that causes COVID-19.
Teen shares his battle with MIS-C following COVID-19 infection
Mar. 7, 2022—Reeyan Ahmed is among the patients treated at Monroe Carell Jr. Children's Hospital at Vanderbilt who developed MIS-C following COVID-19 infection.
COVID-19: two years of challenges, lessons, victories
Mar. 3, 2022—Two years ago this week, the cataclysmic coronavirus known as SARS-CoV-2 arrived in Middle Tennessee.
Study shows young, healthy adults died from COVID-19 due to ECMO shortage
Feb. 25, 2022—Vanderbilt research found that nearly 90 percent of COVID-19 patients who qualified for, but did not receive, ECMO due to a shortage of resources during the height of the pandemic died in the hospital, despite being young with few other health issues
MIS-C diagnosis rare in vaccinated children with no previous COVID-19 diagnosis
Feb. 24, 2022—A Vanderbiltl study found that children who received the COVID-19 vaccine who had not previously been diagnosed with COVID infection are unlikely to be diagnosed with multisystem inflammatory syndrome in children (MIS-C).
Pandemic leads to broader use of monoclonal antibodies
Feb. 17, 2022—Antiviral drugs and coronavirus-fighting monoclonal antibodies, including those discovered at Vanderbilt University Medical Center, remain crucially important in the continuing fight against COVID-19.
Gene variants increase risk of kidney failure in veterans of African ancestry with COVID-19: study
Feb. 10, 2022—Gene variants increased the risk of acute kidney injury and death in veterans of African ancestry who were hospitalized with COVID-19, possibly explaining some health disparities associated with COVID-19.
Vanderbilt and CDC research shows third vaccine dose key to preventing omicron hospitalization
Feb. 9, 2022—Vanderbilt research shows that two doses of an mRNA COVID-19 vaccine result in lower effectiveness for preventing hospitalization for the omicron variant than previous variants. However, importantly, a third (“booster”) vaccine dose significantly improves protection against omicron hospitalization up to 86%.
Study shows life-saving benefit of baricitinib for ventilated COVID patients
Feb. 7, 2022—Vanderbilt research shows that critically ill COVID-19 patients on a mechanical ventilator or extracorporeal membrane oxygenation lived more often when randomized to receive baricitinib.
Advanced Practice Grand Rounds explores COVID’s impact
Feb. 3, 2022—The recent VUMC Advanced Practice Grand Rounds explored the impact the ongoing COVID-19 pandemic is having on the nursing workforce.
Vanderbilt recruiting children to study allergic responses to COVID-19 mRNA vaccines
Jan. 24, 2022—Vanderbilt is conducting a clinical trial to determine risk and mechanisms of allergic reactions to COVID-19 Pfizer-BioNTech mRNA vaccine among children.
Omicron evades some but not all monoclonal antibodies: study
Jan. 20, 2022—A new study found that several, but not all, of the human monoclonal antibodies used clinically to prevent patients from becoming severely ill from COVID-19 may not be protective against the Omicron variant now sweeping across the United States.